Discover MabDesign
MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.
Access our network
Join the MabDesign network to take advantage of all the advantages and opportunities offered.
Develop your skills
Consult and register for our next training courses in order to acquire new expertise.
Explore our business services
The field of therapeutic antibodies and immunotherapy is growing rapidly. The French industrial ecosystem is rich in innovative companies with considerable potential. MabDesign’s mission is to support them in their development in France and abroad.
Our News
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation
Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI to Advance Scientific Instrumentation and Accelerate Laboratory Performance
Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI to Advance Scientific Instrumentation and Accelerate Laboratory Performance
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
OSE Immunotherapeutics Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal
antibody fragment originally discovered and developed by OSE Immunotherapeutics and licensed to Veloxis
in 2021 for all transplant-related indications. Veloxis is responsible for the global development,
manufacturing, and future commercialization of the product.
OUR BOARD OF DIRECTORS
